Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination

Autor: Diego Martin Flichman, Adriana Alter, Sandra Gallego, Federico A. Di Lello, Roberto Fernández, Sebastián Blanco, Claudio Galli, Rosángela Ruiz, Fabiana Vargas, Jorgelina L. Blejer, Alfredo P. Martínez, Sonia Bartoli
Rok vydání: 2020
Předmět:
Male
HBsAg
Pediatrics
VACCINE
Ciencias de la Salud
Blood Donors
medicine.disease_cause
0302 clinical medicine
Seroepidemiologic Studies
Medicine
030212 general & internal medicine
ANTI-HBS TITERS
Child
education.field_of_study
Transmission (medicine)
Age Factors
Middle Aged
Hepatitis B
Vaccination
Titer
Infectious Diseases
Child
Preschool
Molecular Medicine
Female
Adult
Hepatitis B virus
medicine.medical_specialty
CIENCIAS MÉDICAS Y DE LA SALUD
Adolescent
HEPATITIS B VIRUS
030231 tropical medicine
Population
Argentina
Young Adult
03 medical and health sciences
Humans
Seroprevalence
Hepatitis B Vaccines
Hepatitis B Antibodies
education
Hepatitis B Surface Antigens
General Veterinary
General Immunology and Microbiology
business.industry
Public Health
Environmental and Occupational Health
medicine.disease
Enfermedades Infecciosas
business
Zdroj: Vaccine. 38:2678-2682
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2020.02.014
Popis: Universal vaccination is the most effective strategy to control hepatitis B virus (HBV) infection. In Argentina, vaccination against HBV was incorporated in year 2000 for newborns and in 2003 for 11 years old children. However, there is a paucity of data about protection levels against HBV infection. The aim of this work was to determine the prevalence of seroprotective anti-HBs antibodies (aHBs) in Argentina. Serum samples negative for HBsAg and anti-HBc from 132 children born after year 2000 and 762 blood donors, older than 18 years, from five centers across the country, were analyzed for aHBs. Titers ¡Ý10 mIU/mL were observed in 74/132 children (56.1%) and 336/762 (44.1%) in blood donors. The median age for blood donors was 33.9 (23¨C43); from them, 210 (27.6%) were born after 1992 and, therefore, were catch-up by vaccine implementation at 11 years old age. Donors born in 1992 or before showed a significantly lower frequency of protection (32.2%) compared to donors born after 1992 (75.2%), p < 0.0001. In addition, significant differences were observed in the status of seroprotection between different participating centers (p = 0.024). Implementation of HBV vaccine in 2000 and 2003 implied an overall increase of the aHBs seroprotective rates, with a particularly adequate response in children vaccinated at 11 years old age. The observed results suggest that population born in 1992 or before is currently the most susceptible. Consequently, it would be advisable to become aware of the risk of transmission in this age group and to stress this population vaccination campaigns. Fil: Di Lello, Federico Alejandro. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Blejer, Jorgelina L.. Fundación Hemocentro; Argentina Fil: Alter, Adriana. Fundación Hemocentro; Argentina Fil: Bartoli, Sonia. Centro Regional de Hemoterapia Jujuy; Argentina Fil: Vargas, Fabiana Alejandra. Centro Regional de Hemoterapia de Mendoza; Argentina Fil: Ruiz, Rosángela. Hospital Regional Rio Grande; Argentina Fil: Galli, Claudio. Hospital Regional Rio Grande; Argentina Fil: Blanco, Sebastian. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina. Fundación Banco Central de Sangre; Argentina Fil: Gallego, Sandra Veronica. Fundación Banco Central de Sangre; Argentina. Universidad Nacional de Córdoba. Facultad de Medicina; Argentina Fil: Fernández, Roberto. Fundación Hemocentro; Argentina Fil: Martínez, Alfredo P.. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Flichman, Diego Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Databáze: OpenAIRE
Externí odkaz: